Didn’t invite Siddaramaiah because he ignored our previous invitations: Pejawar seer

Karwar: The number of Covid-19 patients in Uttara Kannada district has gone up to 39 with seven more persons from Bhatkal testing positive for the virus on Sunday.

These seven persons include five men and two women. Among them, the youngest is 15 years and the eldest is 60 years. Rest of the patients are 50, 21, 16, 42, and 31 years old, a health bulletin said. All the new seven cases are contacts of the eight persons who were found positive on Saturday.

Of the new cases, one is an auto-rickshaw driver who had reportedly transported one of the patients. Now the administration is collecting the details of the driver’s journeys and the persons who had travelled in his auto-rickshaw. It is said that some of these persons who were confirmed positive on Sunday had travelled to Udupi and moved around in Bhatkal town to buy medicine.

The pressure on the administration is increasing with new positive cases being detected in Bhatkal town every day. After the first 11 cases, there were no new cases for 20 days. However, since Friday, there is sudden spike in the number of new cases in Bhatkal town.

Bengaluru, Apr 25: With 26 new COVID-19 cases confirmed in the past 24 hours, the total number of positive cases in Karnataka reached 500 on Saturday.

This includes 158 patients who have been cured and discharged following treatment while 18 deaths have been reported so far due to the infection in the State, according to a media bulletin issued by the Department of Health and Family Welfare on Saturday evening.

A total of 324 COVID-19 cases are currently active in the State as of Saturday evening 5 pm.
According to the bulletin, Bengaluru Urban with 133 positive cases, including 49 discharged and four deaths, is the worst-affected district in the State, followed by Mysuru and Belagavi, with 89 and 54 confirmed cases, respectively.

The United States of America has bought almost the entire world's supply of remdesivir, one of just two drugs proven to treat COVID-19. 

“President Trump has struck an amazing deal to ensure Americans have access to the first authorised therapeutic for Covid-19,” said the US health and human services secretary, Alex Azar. 

“To the extent possible, we want to ensure that any American patient who needs remdesivir can get it. The Trump administration is doing everything in our power to learn more about life-saving therapeutics for Covid-19 and secure access to these options for the American people.”

The announcement implies that no other country in the world will be able to buy remdesivir for next three months at least.

The anti-viral drug patented by the US-based Gilead biotech firm is the only one approved by the European Medicines Agency (EMA) to treat patients with the novel coronavirus.

The Trump administration has already shown that it is prepared to outbid and outmanoeuvre all other countries to secure the medical supplies it needs for the US.

“They’ve got access to most of the drug supply [of remdesivir], so there’s nothing for Europe,” said Dr Andrew Hill, senior visiting research fellow at Liverpool University.

Remdesivir, the first drug approved by licensing authorities in the US to treat Covid-19, is made by Gilead and has been shown to help people recover faster from the disease. 

The first 140,000 doses, supplied to drug trials around the world, have been used up. The Trump administration has now bought more than 500,000 doses, which is all of Gilead’s production for July and 90% of August and September.